Partners will develop and test mAbs for liver proteins.

Protagen entered into an international collaboration to develop antibodies against liver proteins with the Centre for Applied Proteomics (ZAP), Schunde Kangdi Antibody Biotech, and the Beijing Proteome Research Centre (Beijing PRC).


The involvement of Protagen in the collaboration will be to develop tailor-made protein biochips that can be used to analyze quantitative antibody-binding profiles as well as any off-target activities of antibody candidates. Protagen’s UNIchip® is a research tool that identifies the most specific antibody candidates at an early stage of development.


ZAP will use the UNIchip® to assess around 200 mAbs, generated by Schunde Kangdi Antibody Biotech and Beijing PRC. The results will be used to identify those antibodies that are most promising for future development as research tools, therapeutics, or for use in diagnostic kits. The industrial partners are sharing the worldwide commercialization rights for the antibodies analyzed.

Previous articlep53 May Help Cancer Thrive
Next articleBio-Rad Acquires DiaMed For Over $391M